World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
104
Citations
43234
World Ranking
7010
National Ranking
3684

Eileen M. O’Reilly publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Eileen M. O’Reilly sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 654 publications — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Eileen M. O’Reilly D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Eileen M. O’Reilly sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 104 D-Index — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Eileen M. O'Reilly is affiliated with Memorial Sloan Kettering Cancer Center in the United States. Their research work spans multiple areas in medicine, particularly in oncology, where they have contributed significantly to the study of cancer biology and treatment methodologies.

Their publication record includes numerous papers focused on pancreatic cancer and related oncological fields. Notable recent papers include:

  • "Pancreatic Cancer," published in 2021 in JAMA
  • "Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer," published in 2023 in Nature
  • "Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients," published in 2022 in Cell
  • "Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation," published in 2020 in Journal of Clinical Oncology
  • "Preoperative Treatment of Locally Advanced Rectal Cancer," published in 2023 in New England Journal of Medicine

Their core fields of study are medicine and biochemistry, genetics, and molecular biology. Within these broader domains, their subfields predominantly cover oncology, cancer research, pulmonary and respiratory medicine, surgery, and molecular biology.

Key topics addressed in their research include:

  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Renal Cell Carcinoma Treatment
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Colorectal Cancer Treatments and Studies
  • Neuroendocrine Tumor Research Advances

O'Reilly has frequently published in high-impact journals with a substantial number of papers appearing in:

  • Journal of Clinical Oncology
  • Cancer Research
  • Annals of Oncology
  • Annals of Surgical Oncology
  • Neuromuscular Disorders

Collaborations with other researchers are prominent in their career. Their most frequent co-authors include:

  • Wungki Park
  • Jeffrey A. Meyerhardt
  • Kenneth H. Yu
  • Anna M. Varghese
  • Ghassan K. Abou-Alfa

Best Publications

  • Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

    Talia Golan;Pascal Hammel;Michele Reni;Eric Van Cutsem

  • Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers

    Ayuko Hoshino;Ayuko Hoshino;Han Sang Kim;Han Sang Kim;Linda Bojmar;Linda Bojmar;Linda Bojmar;Kofi Ennu Gyan

  • Pancreatic Cancer: A Review

    Wungki Park;Akhil Chawla;Eileen M O'Reilly;Eileen M O'Reilly

  • Pancreatic adenocarcinoma, version 2.2017: Clinical practice guidelines in Oncology

    Margaret A. Tempero;Mokenge P. Malafa;Mahmoud Al-Hawary;Horacio Asbun

  • Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

    Hedy Lee Kindler;Donna Niedzwiecki;Donna Hollis;Susan Sutherland

  • Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection.

    Itaru Endo;Mithat Gonen;Adam C. Yopp;Kimberly M. Dalal

  • Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

    Alan P. Venook;Donna Niedzwiecki;Heinz Josef Lenz;Federico Innocenti

  • Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

    Philip A. Philip;Jacqueline Benedetti;Christopher L. Corless;Ralph Wong

  • Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    Manish A. Shah;Ramesh K. Ramanathan;David H. Ilson;Alissa Levnor

  • Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer

    Alicia Latham;Preethi Srinivasan;Yelena Kemel;Jinru Shia

  • Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC).

    A. Duffy;M. Capanu;G.K. Abou-Alfa;D. Huitzil

  • Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

    Eileen M. O'Reilly;Do Youn Oh;Neesha Dhani;Daniel J. Renouf

  • Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma

    Joseph M. Herman;Daniel T. Chang;Karyn A. Goodman;Avani S. Dholakia

  • Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing

    Diana Mandelker;Liying Zhang;Yelena Kemel;Yelena Kemel;Zsofia K. Stadler;Zsofia K. Stadler

  • Intrahepatic Cholangiocarcinoma: expert consensus statement

    Sharon M. Weber;Dario Ribero;Eileen M. O'Reilly;Norihiro Kokudo

  • Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.

    Maeve A. Lowery;Ryan Ptashkin;Emmet Jordan;Michael F. Berger

  • Impact of primary (1{o}) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

    Alan P. Venook;Donna Niedzwiecki;Federico Innocenti;Briant Fruth

  • Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

    Davendra P.S. Sohal;Pamela B. Mangu;Alok A. Khorana;Manish A. Shah

  • Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix.

    Laura H Tang;Jinru Shia;Robert A Soslow;Deepti Dhall

  • Tumour lineage shapes BRCA-mediated phenotypes.

    Philip Jonsson;Chaitanya Bandlamudi;Michael L Cheng;Michael L Cheng;Preethi Srinivasan

Frequent Co-Authors

Ghassan K. Abou-Alfa
Ghassan K. Abou-Alfa Memorial Sloan Kettering Cancer Center
David P. Kelsen
David P. Kelsen Memorial Sloan Kettering Cancer Center
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center
Peter J. Allen
Peter J. Allen Duke University
David S. Klimstra
David S. Klimstra Yale University
Michael F. Berger
Michael F. Berger Memorial Sloan Kettering Cancer Center
Alan P. Venook
Alan P. Venook University of California, San Francisco
Manish A. Shah
Manish A. Shah Cornell University
Hedy L. Kindler
Hedy L. Kindler University of Chicago
Jeffrey A. Meyerhardt
Jeffrey A. Meyerhardt Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA doesn’t have to mean the traditional path of medical school. Many students are turning to flexible, online alternatives that offer career opportunities in healthcare. For example, if you are interested in a fast entry into the medical field, medical coding is a promising option. Discover the requirements and expenses involved by reading how much does it cost to become a medical coder.

Nursing is another popular pathway. There are a number of online nurse practitioner programs that allow you to advance your clinical skills while studying remotely. Entry-level nursing is also accessible online; some of the cheapest online nursing program options can make this career more affordable than ever.

For those already holding a nursing degree, an advanced credential can open doors to leadership and research roles. You can see a selection of online phd nursing programs designed for working professionals.

These online degrees provide flexible pathways into growing healthcare careers, often at a lower cost and faster pace than traditional routes.

Best Scientists Citing Eileen M. O’Reilly

Trending Scientists

Recently Published Articles